| clinical trial | Q30612 |
| scholarly article | Q13442814 |
| P2093 | author name string | D. Y. C. Heng | |
| J. M. Ruiz-Morales | |||
| P2860 | cites work | mTOR inhibitors in advanced renal cell carcinoma | Q24612127 |
| Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives | Q26751341 | ||
| Renal cell carcinoma: histological classification and correlation with imaging findings | Q26799781 | ||
| HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors | Q42819341 | ||
| Expression and localization of VEGF receptors in human fetal skeletal tissues | Q50780688 | ||
| Renal cancer. | Q50941188 | ||
| Skeletal complications and survival in renal cancer patients with bone metastases | Q52847077 | ||
| Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma | Q53354192 | ||
| Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR? | Q54224544 | ||
| Next-generation Sequencing of Urologic Cancers: Next Is Now | Q57288433 | ||
| Out of air is not out of action | Q58199718 | ||
| Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial | Q59571527 | ||
| Hepatocyte growth factor can substitute for M-CSF to support osteoclastogenesis | Q79193387 | ||
| Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy | Q81267790 | ||
| Comprehensive molecular characterization of clear cell renal cell carcinoma | Q27852374 | ||
| Integrated molecular analysis of clear-cell renal cell carcinoma | Q27852382 | ||
| Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma | Q28247085 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma | Q33409916 | ||
| Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy | Q34007924 | ||
| Cabozantinib in progressive medullary thyroid cancer | Q34185084 | ||
| Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | Q34217927 | ||
| Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | Q34495684 | ||
| Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma | Q34553839 | ||
| Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 | ||
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Q34633525 | ||
| Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial | Q34650664 | ||
| Drug development of MET inhibitors: targeting oncogene addiction and expedience | Q34782774 | ||
| Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. | Q34896252 | ||
| Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures | Q35684252 | ||
| Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors | Q35927501 | ||
| c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma | Q36551653 | ||
| Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer | Q36822111 | ||
| Targeting MET and Vascular Endothelial Growth Factor Receptor Signaling in Castration-Resistant Prostate Cancer | Q36931715 | ||
| Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen | Q36954859 | ||
| Molecular biology of renal cortical tumors | Q37320998 | ||
| Controlling escape from angiogenesis inhibitors | Q37672654 | ||
| VHL and HIF signalling in renal cell carcinogenesis | Q37708208 | ||
| Targeting MET in cancer: rationale and progress | Q37978193 | ||
| Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor | Q38206456 | ||
| A phase I study of cabozantinib (XL184) in patients with renal cell cancer. | Q38430335 | ||
| Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail. | Q38832659 | ||
| Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma | Q38835745 | ||
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. | Q38859789 | ||
| Hepatocyte growth factor-induced BMP-2 expression is mediated by c-Met receptor, FAK, JNK, Runx2, and p300 pathways in human osteoblasts | Q39364581 | ||
| Hepatocyte growth factor is secreted by osteoblasts and cooperatively permits the survival of haematopoietic progenitors. | Q40828878 | ||
| Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation | Q40881030 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal cell carcinoma | Q1164529 |
| P304 | page(s) | 338-347 | |
| P577 | publication date | 2016-12-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Therapeutic advances in urology | Q26842184 |
| P1476 | title | Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience | |
| P478 | volume | 8 |
| Q47143379 | A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma |
| Q39235281 | An overview of quinoline as a privileged scaffold in cancer drug discovery |
| Q47177700 | Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression |
| Q92707858 | First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer |
| Q42682360 | Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. |
| Q58585079 | Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice |
| Q91809322 | The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment |
| Q90611117 | The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas |
Search more.